Clinical Trials Logo

Stroke clinical trials

View clinical trials related to Stroke.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06459401 Completed - Stroke Clinical Trials

Effects of an Overground Propulsion Neuroprosthesis in Community-dwelling Individuals After Stroke

Start date: February 22, 2021
Phase: Early Phase 1
Study type: Interventional

This interventional study evaluates the effects of an overground propulsion neuroprosthesis that delivers adaptive neurostimulation assistance to the paretic plantarflexors and dorsiflexors of people post-stroke. Individuals with chronic post-stroke hemiparesis will walk with and without the neuroprosthesis overground and on a treadmill. The goal of the study is to understand how adaptive neurostimulation delivered by the neuroprosthesis affects clinical and biomechanical measures of walking function in order to guide future rehabilitation approaches for restoring walking ability after stroke.

NCT ID: NCT06451731 Completed - Stroke Clinical Trials

Rehabilitation of Post-stroke Aphasia by Targeting Phonological, and Lexico-semantic Deficits With Speech Output Tasks

Start date: June 1, 2015
Phase: N/A
Study type: Interventional

Aphasia in brain-damaged adult patients refers "to the more or less complete loss of the ability to use language" resulting from acquired brain damage, typically of the left hemisphere. The defective spoken output of persons with aphasia (PWA) has anomia as a main clinical manifestation. Improving anomia is a main goal of any language treatment. The present randomized controlled study assessed the effectiveness of a novel, two-week, rehabilitation protocol (PHOLEXSEM), focused on PHonological, SEmantic, and LExical deficits, aiming at improving lexical retrieval, and, generally, spoken output. The effects of the PHOLEXSEM treatment were compared to those of a control treatment, i.e., a Promoting Aphasics Communicative Effectiveness (PACE) protocol. Finally, we studied the effects of age, education, disease duration, brain lesion volume, and functional independence (Functional Idependence Measure, FIM) on the treatment-induced linguistic improvements.

NCT ID: NCT06447649 Completed - Stroke Clinical Trials

Investigation of Factors Affecting Shoulder Pain in Stroke Survivors

Start date: December 1, 2019
Study type: Observational

The aim of this study was to examine the factors affecting shoulder pain in stroke survivors and to determine how much the factors affect shoulder pain

NCT ID: NCT06445998 Completed - Stroke Clinical Trials

Effect of Task Oriented Training on Cognitive Function in Elderly Stroke Patients

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Background: The impact of stroke at the time of diagnosis is on the attention and executive functions, which may be impaired at various post-stroke intervals. Objective: To improve Cognitive Function in Elderly Stroke Patients through Task Oriented Training. Subjects and methods: Forty Elderly stroke patients from both sexes assigned randomly into two equal groups. In Group A were allocated to task oriented training in addition to traditional physical therapy program, group B received traditional physical therapy program, three sessions/week for 3 months. Cognitive Function assessed by Reha-com device, Addenbrooke's Cognitive Examination Revised (ACE-R) test and Montreal Cognitive Assessment Scale (MoCA), measured at baseline and after 3 months.

NCT ID: NCT06438770 Completed - Stroke Clinical Trials

Prediction of Gait After Stroke; an External Validation

Start date: July 1, 2020
Study type: Observational

The aim of this observational study is to perform a temporal and geographical external validation of the EPOS (Early Prediction of Outcome after Stroke) model for the prediction of independent gait after stroke. The EPOS model measures the early presence of leg strength on the affected side and sitting ability to predict recovery of independent walking six months after stroke. Compared to the EPOS model development study, the prediction time point of independent gait in this study will be three months rather than six months post-stroke and the patients will be more heterogeneous. Due to the differences in the new cohort, it is expected that the performance of the models will be lower than in the development cohort, but still be adequate.

NCT ID: NCT06437626 Completed - Clinical trials for Ischemic Stroke, Acute

MEXIDOL® Sequential Therapy of Patients With Acute Cerebral Failure

Start date: November 18, 2019
Phase: Phase 3
Study type: Interventional

Cerebral stroke is one of the most pressing clinical and social problems of modern medicine. According to WHO estimates, acute cerebral failure rank second among all causes of death. Optimizing the treatment of such conditions remains an urgent problem in neurology and rehabilitation.

NCT ID: NCT06429384 Completed - Clinical trials for Acute Ischemic Stroke

Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial

Start date: June 4, 2023
Phase: Phase 2
Study type: Interventional

The objective of this clinical trial was to explore the efficacy and safety of Y-3 injection at different doses in patients with acute ischemic stroke within 48 hours of onset. A multicenter, randomized, double-blind, parallel, placebo-controlled trial design was designed to include 240 participants. Subjects press 1:1:1: 1 ratio of patients were randomly divided into Y-3 low-dose group (20 mg/ time, qd), medium-dose group (40 mg/ time, qd), high-dose group (60mg/ time, qd) and placebo control group, with 60 cases in each group. Random stratification factors include: Time of onset (≤24 hours, > 24 hours). The patients were treated for 10 consecutive days (10 times) and followed up to 90 days after the first dose. The trial was divided into three phases: screening/baseline, treatment, and follow-up. Screening/baseline period: Subjects enter the screening/baseline period for screening examination after signing the informed consent. Treatment period: Eligible subjects were randomly assigned at a ratio of 1:1:1:1 to receive Y-3 injection low-dose group, medium-dose group, high-dose group and placebo control drug for 10 consecutive days (10 times), during which relevant examinations required by the protocol were conducted and safety was assessed. Follow-up period: Participants who finished treatment were followed up until 90 days after the first dose. Stroke-related scale scores were performed at 10, 30, and 90 days after first use of the investigational drug The scores of Montgomery Depression Rating Scale (MSAS) and Hamilton Anxiety Scale (HAMA) were performed on the 10th and 90th days after the use of experimental drugs. Adverse events were recorded during treatment and follow-up to further assess safety

NCT ID: NCT06422572 Completed - Stroke, Ischemic Clinical Trials

Tissue Kallikrein Protect Against Ischemic Stroke

Start date: May 1, 2023
Study type: Observational

The results of previous studies were used to assess the causal association between TK levels and stroke occurrence at 5 and 12 years of follow-up, respectively.

NCT ID: NCT06413732 Completed - Stroke Clinical Trials

The Effect of Dual Task Training in Patients With Stroke

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The aim of this study was to investigate the effect of dual-task training on gait, balance, and quality of life in individuals with stroke. The study included 30 individuals aged 30-80 years with stroke. All participants were assessed using the 10-meter walk test (10MWT), 10MWT under dual-task interaction (DTI), timed up and go (TUG), 30-Second Chair-Stand Test (30s-CST), Berg Balance Scale (BBS), Short Form 36 (SF-36). Participants were randomized into two groups. Both groups received conventional physiotherapy for approximately 1 hour, five days a week. Group I also received dual-task training.

NCT ID: NCT06408636 Completed - Atrial Fibrillation Clinical Trials

Prognostic Role of LA Strain in Acute Myocardial Infarction

Start date: September 2, 2019
Study type: Observational

This is a single-center retrospective observational study in which we consecutively selected patients diagnosed with acute myocardial infarction from September 2019 to March 2024 at the Affiliated Hospital of Xuzhou Medical University. Inclusion criteria: 1. CMR was completed during all hospitalizations; 2. complete clinical data; 3. received continuous cardiac monitoring during hospitalization. Exclusion criteria: 1. unclear or non-compliant CMR images; 2. previous history of myocardial infarction; 3. malignant tumors diseases. Dedicated cardiovascular imaging software CVI42 (cvi42® version 5.13.5, Circle Cardiovascular Imaging, Canada) was used for image analysis. LA strain was obtained by cardiac MRI feature tracking. Patient prognosis was obtained through chart notes and telephone follow-up. Major events included atrial fibrillation, ischemic stroke, and all-cause mortality.